Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

US9381243B2 · kind B2 · utility

Assignee

• Rigshospitalet · DK

Inventors

• Pär Johansson · Dösjebro, SE
• Sisse Rye Ostrowski · Copenhagen, DK

Key dates

• Filing date: Jul 11, 2014
• Grant date: Jul 5, 2016
• Expiry date: Jul 14, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.